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1. Introduction
Several diseases can be observed in patients submitted to hemodialysis treatment. Besides
all variants of renal failure, hypertension and diabetes are the most common disorders that
can be observed among these patients.
On the other hand, diagnosis of rare inherited diseases is more difficult and often done too
late, because knowledge about them is limited, included among medical staff. It is estimated
that 6-8% of the population in general will lead to some kind of rare disease and about 80%
of that have a genetic background.
Although this is an extensive theme, the goal of this chapter is describe briefly two group of
rare inherited conditions observed in patients submitted to hemodialysis: (1) tubular and (2)
glomerular diseases. The major clinical features, genetic and molecular aspects and the man‐
agement of the patient will be presented in the next pages.
2. Tubular diseases
2.1. Polycystic Kidney Diseases (PKD)
Up to 10-15% of the patients in hemodialysis can present cystic kidneys and different diseas‐
es with several phenotypes should be considerate in these situations. The autosomal domi‐
nant (ADPKD) and recessive (ARPKD) polycystic kidney diseases are the most important
examples of these clinical conditions.
© 2013 Nunes et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Approximately 50% of patients with ADPKD progress to End Stage Renal Disease (ESRD).
In most cases, regular clinical monitoring is essential and the adoption of a method of renal
replacement therapy (RRT - hemodialysis, peritoneal dialysis or transplantation) becomes
indispensable in the treatment.
Reference Year Etnicity % ADPKD
Iglesias et al. 1983 Euro-descendant 2.75
Gabow 1993 Euro-descendant 8-10
Sesso et al. 1994 Euro-descendant 3
Higashira et al. 1998 Asian 2.5
Glassberg et al. 1998 Caucasian 10
Hwang et al. 2000 Asian 3.2
Nunes et al. 2008 Euro-descendant 7.5
Harris < Torres 2009 Euro-descendant 4.4
Table 1. Percentage of ADPKD among hemodialysis patients.
Although an apparent 100% penetrance, is considered to ADPKD heterogeneous genetic
viewpoint, caused by mutations in one of two genes known to be associated with the dis‐
ease: PKD1 (polycystic kidney disease 1), located in chromosome 16p13.3 and PKD2 (poly‐
cystic kidney disease 2), mapped on 4q21. Most cases (80-85%) results from mutations in
PKD1, causing ADPKD type 1 ADPKD1. In the remaining patients (15-20%) mutations are
identified in PKD2 and give rise to ADPKD type 2 ADPKD2.
The PKD1 gene encompasses 46 exons distributed over a genomic segment of about 52kb
to produce a 14.2 kb mRNA and associated with an open reading frame of approximately
12.9 kb. The PKD1 gene encoding polycystin-1 (PC1), an integral membrane glycoprotein
of  4303 amino acids.  The PC1 has a large extracellular  amino-terminal  portion with ap‐
proximately 3000 amino acids,  11 transmembrane domains and a short  intracellular car‐
boxy-terminal  portion.  The  extracellular  portion  has  a  complex  combination  of  fields,
apparently  involved  in  protein-protein  and  protein-carbohydrate  bindings.  This  group
comprises many domains types, like 16 copies of a repeat of 80 amino acids to similar re‐
gions of immunoglobulin domains PKD, a signal sequence segments of the leucine-rich re‐
peats,  a  domain  WSC,  lectin-binding  domains  of  type-C  and  LDL-A  plus  a  field  REJ
(receptor for egg jelly) domain and a GPS domain.
PKD2 gene, in turn, expresses a 5.4 kb mRNA which encodes a polypeptide of 968 amino
acids, polycustin-2 (PC2). The PC2 has six transmembrane domains and the two tails, amino
and carboxy terminals, are intracytoplasmic.
Furthermore, PC2 shows homology with the last six transmembrane domains of PC1. To‐
gether, the polycystins form a subfamily to the part TRP channels (transient receptor poten‐
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tial). The PC2 works also as a channel of non-selective cation permeable to Ca++, whose
activity is regulated by PC1. Note also the presence of a field EF hand in the carboxy-termi‐
nus of PC2, involved in binding to Ca++.
Of clinical point of view, although both forms are similar in their phenotypes, the greater
severity ADPKD1 shows that ADPKD2, and the median age at diagnosis and progression to
ESRD are lower. In addition, the patient is more likely to ADPKD1 hypertension, hematuria
and urinary tract infections. The early development of a greater number of cysts in patients
with ADPKD1 explain the fact seems to be virtually thus more serious than ADPKD2, since
there seems no difference between these two forms on the rate of formation and/or cystic
expansion. In terms of phenotype, ADPKD presents a great variability between different
families and between members of one family. Cases of infants born to families living with
ADPKD, with signs of established disease are good examples of this variability.
Several studies agree that this model of two events, also known as ‘second hit’, might ex‐
plain the heterogeneous and focal mechanism of cyst formation of ADPKD kidney and liver.
This process, which can be applied to both forms of genetic disease (ADPKD1 and
ADPKD2) has the first blow the germline mutation inherited from one parent and all
present in the patient's renal tubular cells, while the second event is represented by a somat‐
ic mutation in allele previously normal gene.
In addition to the genetic locus involved in the disease, the position of intragenic germline
mutation and the nature of some mutations may account for the variation clinical interfami‐
ly, but cannot explain how a germline mutation subjects with common phenotype can sig‐
nificantly different. The specific type of this mutation does not appear to correlate with the
phenotype of a decisive manner, but mutations located at the 5’ portion of the PKD1 gene
have been associated with progression to ESRD earlier than other positioned at the 3’ por‐
tion of the same gene. Furthermore, the presence aneurysm also was more prevalent in pa‐
tients with mutations in the 5’ PKD1.
Recently, some studies in animal models are supporting the hypothesis that there is still a
‘third hit’ involved in the evolution of ADPKD. According to this hypothesis, the genetic ba‐
sis associated events to accelerate cystogenesis in adult kidney may contribute to the clinical
variability of ADPKD and its prognosis. Experiments carried out in animal models of ische‐
mia/reperfusion demonstrated that the ischemic insult can be considered as additional blow
to the formation of kidney cysts.
In fact, comparative observations between identical twins and siblings show that the regular
course of renal disease is heterogeneous even among individuals with similar genetic herit‐
age. Another important aspect is the fact that mechanisms of different nature, can influence
the rate of somatic mutations on renal tubular epithelial cells, can potentially interfere with
the severity of renal phenotype, also contributing to the observed variability in ADPKD.
Family history is essential for the diagnosis of ADPKD. For preparation of the interview
should be alert to family history of cystic disease, with or without renal impairment. By
presenting  a  pattern  of  dominant  inheritance,  are  expected  to  be  found  members  of
ADPKD patients in all generations. However, the occurrence of new cases should be con‐
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sidered  in  those  genealogies  where  prior  registration  is  not  found in  polycystic  kidney
disease or kidney disease.
In the absence of a family history, which occur about 10% of all cases, the presumptive diag‐
nosis may be done with evidence of bilateral renal cysts, according to criteria recently stand‐
ardized by Pei et al. (2009). The adoption of more specific criteria relating to age of the
patient increased the predictive value of diagnostic imaging. Furthermore, the inclusion of
genetic tests, such as genetic linkage studies or direct DNA sequencing also allowed the
identification of new cases with more accuracy and robustness. Besides that, the existence of
one or more of the following criteria should also be considered: bilateral enlargement of the
kidneys, hepatic, pancreatic or spleen cysts, brain aneurysm, cyst arachnoid alone in the
pineal gland and diverticulitis.
The imaging examination is also essential for the diagnosis. In this sense, ultrasonography
(US) is very useful in the diagnosis and can detect cysts from 1.0 to 1.5 cm. The presence of
liver or pancreatic cysts helps confirm the diagnosis. The US diagnostic criteria include the
number of cysts for each kidney and age of patients, as described in Table 2. In terms of sen‐
sitivity, computed tomography (CT) is the imaging test that can detect cysts from 0.5 cm.
However, this test is not as the first choice is to use radiation or by having a higher cost.
Finally, magnetic resonance imaging (MRI) is considered a more accurate tool than the US
and must be requested in cases in which the distinction between carcinoma and renal cysts
becomes necessary. The MRI examination allows detection of cysts from 0.3 cm in diameter
and is able to assess more accurately the size of the kidneys.
Age Diagnostic criteria for Inclusion
15-39 years 3 or more cysts unilaterally or bilaterally
40-59 years 2 or more cysts in each kidney
≥ 60 years 4 or more cysts in each kidney
Diagnostic Criteria for Exclusion
≥ 40 years Less than 2 cysts
Table 2. Diagnostic criteria for ADPKD.
The goal of treatment for patients with ADPKD is to preserve renal function and blood pres‐
sure control. In this context it is important to reduce progression to chronic kidney disease
and monitor the risk of rupture of intracranial aneurysms and subarachnoid hemorrhage.
Another important practice is to guide the patient to avoid sporting activities in which there
is possibility of trauma in the lower back or abdominal in felt to minimize the risk of rupture
of the cysts.
In normotensive patients with normal renal function annual US tests and renal function
must be regular, keeping intervals not exceeding 12 months between assessments. For the
control of blood pressure, angiotensin I to angiotensin converting (ACE), or receptor An‐
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tagonists of angiotensin II (ATII) are the drugs of choice, as the system renin-angiotensin
system plays a central role in the pathophysiology of hypertension in this clinical situa‐
tion.
Inhibition of vasopressin receptor also occupies a significant challenge as a therapeutic
agent for ADPKD, since the increase of these receptors may directly contribute to increase
the concentration of cAMP and interact with many other proteins associated with cyst for‐
mation. Studies with drugs specific to this scenario are underway and their results may help
in clinical management soon.
Abdominal pain is managed with analgesics and rest. Avoid nonsteroidal anti-inflammatory
effect due to the nephrotoxic potential of these drugs. When the cysts become infected pa‐
tients should be hospitalized and monitored. It is recommended in this situation, administer
antibiotics able to penetrate the cyst, such as ciprofloxacin, clindamycin, chloramphenicol
and trimethoprim-sulfamethoxazole.
Surgical intervention may be needed in the following cases: (1) Pain: Acute pain can be
caused by intracystic hemorrhage or renal obstruction, either by clot or lithiasis. Decompres‐
sion of cyst is effective in relieving pain in approximately 60-80% of cases. One option is the
percutaneous drainage followed by instillation of sclerosing substance. Another possibility
is the decortication of cysts by laparotomy. (2) Cysts infected: non-responsive to convention‐
al antibiotic therapy. (3) Nephrectomy: cysts suitable for high volume (> 35cm), recurrent in‐
fections, uncontrolled hypertension and possibility of malignancy. (4) Massive polycystic
liver disease: when liver cysts, due to the large volume, preclude the patient adequate nutri‐
tion or cause severe abdominal discomfort.
2.2. Bartter’s Syndrome (BS)
Bartter syndrome (BS) was so named after Dr. Frederic Bartter, in collaboration with Dr. Pa‐
cita Pronove, describes the first case in 1960. BS is a rare inherited defect in the thick ascend‐
ing limb of the loop of Henle. Hypokalemia (low potassium levels), alkalosis (increased of
blood pH) and normal to low blood pressure and elevated plasma renin and aldosterone are
the major features of this disorder. There are two types of BS: neonatal (NBS) and classic
(CBS). A closely associated disorder, Gitelman’s syndrome (described below) is milder than
both subtypes of Bartter’s syndrome.
NBS are observed between 24 and 30 weeks of gestation with polyhydramnios (excess amni‐
otic fluid) in 90% of cases. In first time after birth, the newborn presents polyuria (excess of
urine production) and polydipsia (excessive thirst). Life-threatening dehydration may result
if the infant does not receive adequate fluids. About 85% of infants dispose of hypercalciuria
(excess of calcium in the urine) and nephrocalcinosis (excess of calcium in the kidneys),
which may lead to kidney stones. In rare occasions, the infant may progress to renal failure.
Patients with CBS may have symptoms in the first two years of life, but they are usually di‐
agnosed at school age or later. Like infants with the neonatal subtype, patients with CBS al‐
so have polyuria, polydipsia, and a tendency to dehydration, but normal or just slightly
increased urinary calcium excretion without the tendency to develop kidney stones. These
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patients also have vomiting and growth retardation. Kidney function is also normal if the
disease is treated, but occasionally patients proceed to ESRD.
Numerous causes of this syndrome probably exist. Diagnostic pointers include high urinary
potassium and chloride despite low serum values, increased plasma renin, hyperplasia of
the juxtaglomerular apparatus on renal biopsy, and careful exclusion of diuretic abuse. Ex‐
cess production of renal prostaglandins is often found. Magnesium wasting may also occur.
The differential diagnosis should be made to avoid mistake with other identical symptoms
like those observed in patients that use furosemide, for example. Although the major clinical
findings characteristic of BS are hypokalemia, metabolic alkalosis, and normal to low blood
pressure, these findings may also be caused by chronic vomiting, abuse of diuretic medica‐
tions and magnesium and calcium deficiencies. These conditions should be available in all
BS suspects.
Different mutations are associated to BS pathophysiology. These mutations are related to
genes that encoding proteins with ions transporter role across renal cells in nephron, mainly
in thick ascending limb.
BS type Common name Mutated gene Deficiency
1 Neonatal Batter’s Syndrome SLC12A2 (NKCC2) Na-K-2Cl symporter
2 Neonatal Batter’s Syndrome ROMK/KCNJ1 Thick ascending limb K+ channel
3 Classic Batter’s Syndrome CLCNKB Cl- channel
4 BS with sensorineural deafness BSND Cl- channel accessory subunit
5 BS associated with autosomal
dominant hypocalcemia
CASR Calcium-sensing receptor (activating
mutation)
Table 3. Major characteristics of different types of BS.
In addition to hemodialysis the BS patient can received specific treatment to avoid the po‐
tassium loss. Spironolactone and potassium supplements can be required. Besides that, an
increased sodium diet also can be associated. In specific cases, angiotensin-converting en‐
zyme (ACE) inhibitors and nonsteroidal anti-inflammatory drugs can also be used, mainly
in NBS patients.
In terms of prognostic, the limitation of knowledge about BS hampers any extrapolation on
this field. In any case, early diagnosis remains the best predictor of successful treatment. For
example, in CBS patients, the early treatment of electrolyte imbalances promotes good re‐
sponses and patients tend to have few developmental failures.
2.3. Gitelman’s Syndrome (GS)
Gitelman’s syndrome (GS) was discovered in 1966 by Dr. Hillel Gitelman. It was discovered
that some patients with BS showed a different myriad of symptoms. GS is also a renal salt
Hemodialysis50
wasting disorder but the defective tubule is in the thiazide-sensitive Na-Cl cotransporter in
the distal convoluted tubule (DCT). Both disorders are associated with hypokalemia, renal
potassium wasting, activation of the renin-angiotensin-aldosterone axis, and normal blood
pressure. Unlike patients with Bartter’s, patients with Gitelman’s syndrome have hypomag‐
nesemia, increased urinary magnesium and decreased calcium excretion.
GS is characterized by a milder and later clinical presentation. Often, this disorder is diag‐
nosed in asymptomatic adults who present with unexplained hypokalemia. Pediatric cases
typically present in the school age period with fatigue, muscle weakness, and symptoms of
neuromuscular irritability. Growth retardation and polyuria-polydipsia are not prominant
features of GS. Joint pain secondary to chondrocalcinosis has been described in this subset of
patients and attributed to the hypomagnesemia.
Diagnosis of GS is distinguished by high plasma renin activity with normal aldosterone se‐
cretion rates, normal urinary prostaglandin excretion, hypocalciuria and usually marked hy‐
pomagnesemia.
Gitelman’s is more common than Bartter’s but is still a rare disorder. There is no racial pre‐
disposition for either BS or GS and both are inherited as autosomal recessive syndromes. Be‐
sides that, there is no gender preference and GS is often not easily diagnosed until
adolescence or early adulthood.
The exact pathogenic mechanism of hypocalciuria and hypomagnesemia in GS is unclear.
However, know that GS is an autosomal recessive kidney disorder caused by loss of func‐
tion mutations of the thiazide sensitive sodium-chloride symporter (also known as NCC,
NCCT or TSC) located in the distal convoluted tubule. This failure is associated to inactivat‐
ing mutations in the SLC12A3 gene. Until the distinct genetic and molecular bases of these
disorders were identified Gitelman’s syndrome was formerly considered a subset of Bart‐
ter’s syndrome.
GS presents a great variability among patients. These phenotypic variations can be associat‐
ed to genetic background and express specifics amino acid changes in the TSC mutated pro‐
tein, which normally reabsorbs about 7% of the filtered NaCl load. This failure function
cause defective Na and Cl reabsorption in the DCT.
Treatments to GS can be combine magnesium and potassium supplementation in associa‐
tion to spironolactone, amilioride and triamterene.
3. Glomerular diseases
3.1. Fabry Disease (FD)
Fabry disease (FD) is a lysosomal storage disorder caused by the deficient α-galactosidase A
(α-gal A) activity. Fabry nephropathy typically progresses throughout the fifth decade to
ESRD requiring hemodialysis and/or kidney transplantation. Except for ESRD development,
a milder phenotype “renal variant” type is characterized with low plasma α-gal A activity.
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FD low prevalence expresses the importance of this investigation among ESRD patients
without known cause. Routine screening of male hemodialysis patients would enable earlier
identification of other family members who might benefit from specific clinical treatment.
The analysis of other epidemiological characteristics of regular FD could be used for the
screening and detection of other kindred who might benefit from specific therapy as well as
their offspring.
FD beginning in childhood, common symptoms include chronic or intermittent numbness;
burning, tingling pain that can occur daily, usually in the fingers and feet; episodic pain that
is incapacitating and may be brought on by stress, exercise, or temperature changes; recur‐
ring fever with elevated erythrocyte sedimentation rate; angiokeratomas that may appear in
adolescence and increase as an adult; opacity of the corneal lens; inability to perspire; severe
abdominal pain; and an intolerance to temperature (heat or cold) and exercise. The condi‐
tion then progresses in adulthood to include renal, cardiovascular, cerebrovascular, and pul‐
monary complications that may lead to ESRD, stroke, myocardial infarction, breathing
problems and obstructions, and more.
FD is a rare inborn error with a recessive X-linkage inherited pattern. The estimated FD inci‐
dence is between 1:40,000 and 1:117,000 in general population. The prevalence of end stage
FD males on dialysis was estimated between 0.22% and 1.2% in several populations.
The enzymatic defect in FD results from the deficient activity of the α-galactosidase A (α-gal
A), a lysosomal hydrolase encoded by a gene (GLA) localized to Xq22. The GLA gene is 12
kb long and consists of 7 exons encoding 429 amino acids including a 31-amino acid signal
peptide. The mature form of α-gal A is a homodimeric glycoprotein with molecular weight
of ~46kDa synthesized from that point on cleavage of the signal peptides with ~50kDa.
In FD this leads to progressive intracellular accumulation of glycosphingolipids, mainly in
the form of globotriaosylceramide (Gb-3), in many cells, particularly in renal epithelial cells,
endothelial cells, pericytes, vascular smooth muscle cells, cardiomyocytes, and neurons of
the autonomic nervous system.
The genetic defect occurs in all cell types, but involvement differs greatly among different
organs and cell types. This heterogeneity likely reflects different rates of sphingolipid me‐
tabolism. Thus the minimum threshold requirement for α-gal A activity to prevent Gb-3 ac‐
cumulation varies across cell types due to the type and amount of substrates that are
recycled by the different cells.
Clinical onset of the disease typically occurs during childhood or adolescence with recurrent
episodes of severe pain in the extremities, characteristic cutaneous lesions know as angio‐
keratomas and a distinctive but asymptomatic corneal dystrophy. Proteinuria and chronic
renal disease occur with increasing age. Severe renal impairment leads to hypertension and
uremia. Without dialysis, transplantation or enzyme replacement therapy (ERT), progres‐
sive renal failure is the main cause of death in the 4th decade of life in most hemizygous
males with FD. However, a number of variants with residual α-gal A activity with late-onset
manifestations primarily limited to the heart or kidney have been described.
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The ‘classical phenotype’ includes the pain and paresthesias in extremities, diffused angio‐
keratoma and hypohidrosis during childhood or adolescence, and also corneal opacities and
renal failure. Fabry nephropathy typically progresses throughout the fifth decade of life to
ESRD requiring hemodialysis and/or kidney transplantation. In view of this fact, hemodialy‐
sis patients represent an important target group for FD screening. Death usually occurs due
to renal failure, cardiac or cerebrovascular disease. In addition, milder variants with residual
α-gal A activity have been described. The cardiac and renal variants present with either late-
onset manifestations primarily limited to the heart or kidney. The ‘renal variant’, a milder
FD phenotype, can present late-onset manifestations primarily limited to the kidney.
While in an epidemiological point of view FD occurrence is low, on the other hand the FD
diagnosis is very important for detection of family members. In view of this fact, dialysis pa‐
tients represent an important target group for FD screening because they permit to identify
FD patients and therefore others carriers among your family members. Each screened con‐
firmed patient could allow early diagnosis of others related subjects, who can get treatment
before or in the earlier symptoms manifestations. In these terms, FD screening among ESRD
patients consists of an important tool for detection of FD patients and it could be followed
by FD screening between family members of the index case. Both pedigree and population
screening studies have been described and it can be carried out in subpopulations thought
to be at higher risk of disease than the general population.
FD patients with proteinuria or CRI should have aggressive treatment of hypertension is
present and should probably be treated preferentially with angiotensin antagonist therapy;
the latter recommendation is based on theoretical considerations, as definitely proof of effi‐
cacy has not been obtained yet.
Two different recombination α-galactosidase-A preparations are in use for treating FD. One
enzyme is produced by Chinese hamster ovary (CHO) cells with classic recombinant tech‐
nology (agalsidase β, Fabrazyme – Genzyme Corporation), and the other enzyme is pro‐
duced by cultured human skin fibroblast with an activated promoter of the α-gal A gene
(Agalsidase α, Replagal – Shire Human Genetics Therapies). Both recombinant enzymes are
quite comparable in properties and differ only alightly in glycan composition. The two en‐
zyme preparations have independently been examined in clinical investigations. Although
both enzyme therapies were found to result in the desired Gb-3 from endothelium, the clini‐
cal effects are not robust as anticipated. In some patients, stabilization of renal function and
improvenment in cardiac hypertrophy occurs upon therapy.
3.2. Alport’s Syndrome (AS)
Alport syndrome (AS) or hereditary nephritis was first identified in a British family by Dr.
Cecil Alport in 1927. It is a genetic disorder characterized by glomerulonephritis, ESRD and
hearing loss. AS can also affect the eyes (lenticonus). Hematuria is almost always found in
this condition.
This disorder is caused by mutations in COL4A3, COL4A4 and COL4A5 genes and/or in
collagen biosynthesis genes. Mutations in any of these genes prevent the proper production
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or assembly of the type IV collagen network, which is an important structural component of
basement membranes in the kidney, inner ear and eye. Basement membranes are thin, sheet-
like structures that separate and support cells in many tissues. When mutations prevent the
formation of type IV collagen fibers, the basement membranes of the kidneys are not able to
filter waste products from the blood and create urine normally, allowing blood and protein
into the urine.
The abnormalities of type IV collagen in kidney basement membranes cause gradual scar‐
ring of the kidneys, eventually leading to kidney failure in many people with the disease.
Progression of the disease leads to basement membrane thickening and gives a "basket-
weave" appearance from splitting of the lamina densa. Single molecule computational studies
of type IV collagen molecules have shown changes in the structure and nanomechanical be‐
havior of mutated molecules, notably leading to a bent molecular shape with kinks.
AS can have different inheritance patterns that are dependent on the genetic mutation. The
pattern most common is X-linked, due to mutations in the COL4A5 gene. Mutations in both
copies of the COL4A3 or COL4A4 genes, located on chromosome 2, confer an autosomal re‐
cessive pattern to mutation bearer. On the other hand, in rare situations (about 5%), some
patients can have clinical features associated to AS autosomal dominant transmission. In
these specific cases, renal failure tends to occur slowly.
The diagnosis of AS can be made according following observations:
1. family history of nephritis of unexplained hematuria in a first degree relative of the in‐
dex case or in a male relative linked through any numbers of females;
2. persistent hematuria without evidence of another possibly inherited nephropathy such
as thin Glomerular Basement Membrane (GBM) disease, polycystic kidney disease or
IgA nephropathy;
3. bilateral sensorineural hearing loss in the 2000 to 8000Hz range. The hearing loss devel‐
ops gradually, is not present in early infancy and commonly presents before the age of
30 years;
4. Mutation in one of the genes associated to disease (COL4A3, COL4A4 or COL4A5);
5. immunohistochemical evidence of complete or partial lack of the Alport epitope in glo‐
merular, or epidermal basement membranes, or both;
6. widespread GBM ultrastructural abnormalities, in particular thickening, thinning and
splitting;
7. ocular lesions including anterior lenticonus, posterior subcapsular cataract, posterior
polymorphous dystrophy and retinal flecks;
8. gradual progression to ESRD in the index case of at least two family members;
9. macrothrombocytopenia or granulocytic inclusions, similar to the May-Hegglin anomaly
and
10. diffuse leiomyomatosis of esophagus or female genitalia, or both.
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Do not have a specific treatment to AS. In this case, treatments are symptomatic and patients
are advised on how to manage the complications of kidney failure and the proteinuria that
develops is often treated with ACE inhibitors, although they are not always used simply for
the elevated blood pressure.
4. Conclusions
Many aspects can be considered in analysis of rare inherited diseases. In this chapter, we de‐
scribed only five different rare inherited disorders possible to observe among hemodialysis
patients. However, is important to comment that other diseases with few population fre‐
quencies should be analyzed in patients with uncommon signals. Besides that, infection dis‐
eases and drugs dependent diseases also should be investigate in some cases. Genetic and
molecular analysis also can be a relevant tool to use in situations of rare clinical presenta‐
tions. A multidisciplinary approach, including the nephrologists and the geneticists besides
others professionals, is the most important strategy to investigate any rare inherited disor‐
der. For these specific uncommon conditions, the linkage between clinical and research
staffs can be improve the diagnosis strategy.
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